Parkman Healthcare Partners LLC Sells 92,915 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)

Parkman Healthcare Partners LLC decreased its holdings in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) by 20.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 352,481 shares of the company’s stock after selling 92,915 shares during the period. Parkman Healthcare Partners LLC owned approximately 0.51% of Bicycle Therapeutics worth $4,935,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Bicycle Therapeutics by 43.3% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 80,236 shares of the company’s stock valued at $1,123,000 after purchasing an additional 24,260 shares during the period. Millennium Management LLC purchased a new position in Bicycle Therapeutics in the 4th quarter worth approximately $2,475,000. Fcpm Iii Services B.V. raised its stake in Bicycle Therapeutics by 47.5% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company’s stock valued at $48,333,000 after buying an additional 1,112,369 shares during the last quarter. Caption Management LLC purchased a new stake in Bicycle Therapeutics during the 4th quarter valued at $2,283,000. Finally, Baker BROS. Advisors LP increased its stake in shares of Bicycle Therapeutics by 15.8% in the 4th quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company’s stock worth $152,395,000 after purchasing an additional 1,485,397 shares in the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Analyst Ratings Changes

BCYC has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Morgan Stanley set a $17.00 price objective on shares of Bicycle Therapeutics and gave the stock an “equal weight” rating in a research report on Monday, May 5th. Barclays lowered their price target on Bicycle Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, May 1st. JMP Securities reduced their price objective on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a “market outperform” rating for the company in a research note on Friday, May 2nd. Finally, Stephens restated an “equal weight” rating and issued a $15.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Bicycle Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $25.00.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ BCYC opened at $8.11 on Wednesday. Bicycle Therapeutics plc has a 52 week low of $6.10 and a 52 week high of $28.67. The stock’s fifty day moving average is $8.36 and its 200 day moving average is $13.53. The stock has a market capitalization of $561.65 million, a P/E ratio of -2.47 and a beta of 1.60.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The firm had revenue of $9.98 million for the quarter, compared to analyst estimates of $8.67 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Equities research analysts forecast that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.